
Susanna Moore
Examiner (ID: 4754)
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624 |
| Total Applications | 1838 |
| Issued Applications | 1086 |
| Pending Applications | 196 |
| Abandoned Applications | 608 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18825267
[patent_doc_number] => 11840537
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Preparation and application of a 5-bromoquinazoline derivative
[patent_app_type] => utility
[patent_app_number] => 17/488317
[patent_app_country] => US
[patent_app_date] => 2021-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 1834
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17488317
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/488317 | Preparation and application of a 5-bromoquinazoline derivative | Sep 28, 2021 | Issued |
Array
(
[id] => 18769303
[patent_doc_number] => 20230364061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => THIAZOLIDINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS
[patent_app_type] => utility
[patent_app_number] => 18/027222
[patent_app_country] => US
[patent_app_date] => 2021-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17875
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027222
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/027222 | THIAZOLIDINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS | Sep 22, 2021 | Pending |
Array
(
[id] => 19543118
[patent_doc_number] => 20240360154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/245167
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1331
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245167
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245167 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sep 20, 2021 | Pending |
Array
(
[id] => 19543118
[patent_doc_number] => 20240360154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/245167
[patent_app_country] => US
[patent_app_date] => 2021-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1331
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245167
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245167 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sep 20, 2021 | Pending |
Array
(
[id] => 18980133
[patent_doc_number] => 11905293
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/477122
[patent_app_country] => US
[patent_app_date] => 2021-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 40112
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477122
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/477122 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | Sep 15, 2021 | Issued |
Array
(
[id] => 18770822
[patent_doc_number] => 20230365621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM
[patent_app_type] => utility
[patent_app_number] => 18/245109
[patent_app_country] => US
[patent_app_date] => 2021-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245109
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245109 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | Sep 13, 2021 | Pending |
Array
(
[id] => 18770822
[patent_doc_number] => 20230365621
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM
[patent_app_type] => utility
[patent_app_number] => 18/245109
[patent_app_country] => US
[patent_app_date] => 2021-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245109
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/245109 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | Sep 13, 2021 | Pending |
Array
(
[id] => 17369884
[patent_doc_number] => 20220024936
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => INHIBITORS OF MENIN-MLL INTERACTION
[patent_app_type] => utility
[patent_app_number] => 17/472583
[patent_app_country] => US
[patent_app_date] => 2021-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17472583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/472583 | Inhibitors of menin-mll interaction | Sep 9, 2021 | Issued |
Array
(
[id] => 18692469
[patent_doc_number] => 20230322724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/044329
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044329
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044329 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Sep 8, 2021 | Pending |
Array
(
[id] => 18692469
[patent_doc_number] => 20230322724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/044329
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044329
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/044329 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | Sep 8, 2021 | Pending |
Array
(
[id] => 17343613
[patent_doc_number] => 20220009944
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/470608
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18681
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470608
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470608 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | Sep 8, 2021 | Issued |
Array
(
[id] => 18692550
[patent_doc_number] => 20230322844
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => PROCESS FOR PREPARING (3alpha,5alpha)-3-HYDROXY-3-METHYL-PREGNAN-20-ONE (GANAXOLONE)
[patent_app_type] => utility
[patent_app_number] => 18/024612
[patent_app_country] => US
[patent_app_date] => 2021-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6387
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024612
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/024612 | Process for preparing (3a,5a)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone) | Sep 7, 2021 | Issued |
Array
(
[id] => 17761481
[patent_doc_number] => 20220235093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => BILE SALT HYDROLASE PROBE AND METHOD OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/469297
[patent_app_country] => US
[patent_app_date] => 2021-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17469297
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/469297 | BILE SALT HYDROLASE PROBE AND METHOD OF MAKING AND USING THE SAME | Sep 7, 2021 | Abandoned |
Array
(
[id] => 17299399
[patent_doc_number] => 20210395238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => NADPH OXIDASE 4 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/466394
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466394
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/466394 | NADPH OXIDASE 4 INHIBITORS | Sep 2, 2021 | Abandoned |
Array
(
[id] => 17641915
[patent_doc_number] => 20220169653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/466230
[patent_app_country] => US
[patent_app_date] => 2021-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23607
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466230
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/466230 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | Sep 2, 2021 | Abandoned |
Array
(
[id] => 18675023
[patent_doc_number] => 20230312570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => METHOD FOR PREPARING MORPHINAN DERIVATIVE HAVING DIARYL ETHER SKELETON USING NOVEL COPPER CATALYST
[patent_app_type] => utility
[patent_app_number] => 18/023461
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 464
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023461
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/023461 | METHOD FOR PREPARING MORPHINAN DERIVATIVE HAVING DIARYL ETHER SKELETON USING NOVEL COPPER CATALYST | Aug 26, 2021 | Pending |
Array
(
[id] => 17297805
[patent_doc_number] => 20210393644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
[patent_app_type] => utility
[patent_app_number] => 17/458631
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10814
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17458631
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/458631 | 4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | Aug 26, 2021 | Pending |
Array
(
[id] => 18675023
[patent_doc_number] => 20230312570
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => METHOD FOR PREPARING MORPHINAN DERIVATIVE HAVING DIARYL ETHER SKELETON USING NOVEL COPPER CATALYST
[patent_app_type] => utility
[patent_app_number] => 18/023461
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 464
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023461
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/023461 | METHOD FOR PREPARING MORPHINAN DERIVATIVE HAVING DIARYL ETHER SKELETON USING NOVEL COPPER CATALYST | Aug 26, 2021 | Pending |
Array
(
[id] => 17748123
[patent_doc_number] => 20220226326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/409644
[patent_app_country] => US
[patent_app_date] => 2021-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41538
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17409644
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/409644 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Aug 22, 2021 | Abandoned |
Array
(
[id] => 18709154
[patent_doc_number] => 20230331766
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE
[patent_app_type] => utility
[patent_app_number] => 18/026888
[patent_app_country] => US
[patent_app_date] => 2021-08-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7070
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026888
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | Aug 22, 2021 | Pending |